Ed Esplin, SVP of Medical Affairs at Biocartis, shared on LinkedIn:
“13.3% of men w/ Prostate Cancer had a positive genetic finding (PGV) on germline genetictesting.
Contrary to common expectations factors, including age at diagnosis, ethnicity, and Gleason score, did not show significant associations w/ PGVs.
Our observation supports universal germlinetesting for all patients w/ Prostate Cancer, regardless of age, ethnicity, or disease stage
- Neal Shore et al. JCO Journals ‘Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now’
- Ed Esplin et al. JCO Journals ‘Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer’
- Vivek Subbiah, Razelle Kurzrock JCO Journals American Society of Clinical Oncology (ASCO) ‘Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis’. “
Other articles featuring Ed Esplin on OncoDaily.